Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

OPKO Connect provides comprehensive support

Patient assistance programs

For patients identified as not having affordable access to Rayaldee therapy, OPKO offers a free drug patient assistance program; eligibility criteria apply and annual re-enrollment is required.

Copay assistance

With this program, eligible commercially insured patients can fill their Rayaldee prescription for no more than $5 per month until the annual maximum limit is reached.

Starter dose program

This program provides a one-time-only free, 14-day supply of product to eligible patients whose initial Rayaldee coverage determination is delayed more than 5 days based on payer review timelines.

Prior authorization support

Can assist with any insurer-required PAs for Rayaldee on behalf of patients.

For information on how to request
exception coverage for Medicare Part D beneficiaries please visit www.cms.gov.

OPKO Connect services are available
by phone at 844‑414‑6756
Monday through Friday, 8 AM‑8 PM ET

Click here to download a Letter of Medical Necessity for Rayaldee Click here to download the Rayaldee Service Request form